The effects of the in vivo treatment with a mAb (DB-1) that neutralizes mouse IFN-gamma on the development of the SLE-like syndrome in MRL/1pr-1pr (MRL-1pr) mice were studied. The results show that the i.p. administration of 2.6 mg/week of DB-1 from the 12th to the 20th week of age neither affected the survival nor the incidence and severity of lupus nephritis in MRL-1pr mice. This study argues against the pathogenic relevance of IFN-gamma in this experimental model of human SLE.
In vivo treatment with a monoclonal antibody to interferon-gamma neither affects the survival nor the incidence of lupus-nephritis in the MRL/lpr-lpr mouse
NICOLETTI, FERDINANDO;DIMARCO R;
1992-01-01
Abstract
The effects of the in vivo treatment with a mAb (DB-1) that neutralizes mouse IFN-gamma on the development of the SLE-like syndrome in MRL/1pr-1pr (MRL-1pr) mice were studied. The results show that the i.p. administration of 2.6 mg/week of DB-1 from the 12th to the 20th week of age neither affected the survival nor the incidence and severity of lupus nephritis in MRL-1pr mice. This study argues against the pathogenic relevance of IFN-gamma in this experimental model of human SLE.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
68.pdf
solo gestori archivio
Tipologia:
Versione Editoriale (PDF)
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
499.93 kB
Formato
Adobe PDF
|
499.93 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
